Recombinant IFNA2 抗体 (PE)
Our Local Distributor
北京 101111
Quick Overview for Recombinant IFNA2 抗体 (PE) (ABIN7867330)
抗原
See all IFNA2 抗体抗体类型
适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
原理
- PE-conjugated Anti-IFNA2 antibody(1B7), IgG1 Chimeric mAb
-
纯化方法
- Purified from cell culture supernatant by affinity chromatography
-
亚型
- IgG1
-
-
-
-
应用备注
- Flow Cyt 1:100
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
缓冲液
- Liquid PBS with 0.05 % Proclin300, 1 % BSA
-
储存液
- ProClin
-
注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C
-
储存方法
- Store at 2°C-8°C for 6 months
-
有效期
- 6 months
-
-
- IFNA2 (Interferon, alpha 2 (IFNA2))
-
别名
- IFNA2
-
背景
-
Synonyms: IFNA, IFNA2B, leIF A, IFN-alphaA, IFN-alpha-2
Target Background: This gene is a member of the alpha interferon gene cluster on chromosome 9. The encoded cytokine is a member of the type I interferon family that is produced in response to viral infection as a key part of the innate immune response with potent antiviral, antiproliferative and immunomodulatory properties. This cytokine, like other type I interferons, binds a plasma membrane receptor made of IFNAR1 and IFNAR2 that is ubiquitously expressed, and thus is able to act on virtually all body cells. The encoded protein is effective in reducing the symptoms and duration of the common cold and in treating many types of cancer, including some hematological malignancies and solid tumors. A deficiency of type I interferon in the blood is thought to be a hallmark of severe COVID-19 and may provide a rationale for a combined therapeutic approach. [provided by RefSeq, Aug 2020]
-
UniProt
- P01563
-
途径
- JAK/STAT Signaling, Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response, Hepatitis C
抗原
-